Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
OrthoPediatrics is a pure-play pediatric orthopedic medical device company focused on designing, developing, and marketing implants and instruments for children with spinal and trauma/deformity conditions. The company operates in a highly specialized niche with limited competition, serving approximately 3,000 pediatric orthopedic surgeons globally through a direct sales force in the US and distributors internationally. With 72.6% gross margins but negative operating margins, KIDS is in a growth-investment phase, expanding its product portfolio through acquisitions and internal development while building market share in an underserved pediatric segment estimated at $1.5-2 billion globally.
KIDS generates revenue through direct sales of single-use implants and reusable instrument sets to hospitals and ambulatory surgery centers. The company commands premium pricing due to limited pediatric-specific competition (most orthopedic companies focus on adult markets with 10x larger volumes). Revenue model is procedure-driven: each surgery generates $3,000-15,000 in implant revenue depending on complexity. The company maintains high gross margins (72.6%) through specialized product design, proprietary sizing for growing bones, and surgeon training programs that create switching costs. Growth strategy combines organic expansion (new surgeon adoption, international markets representing ~25% of revenue) and acquisitions of complementary pediatric portfolios. Operating losses reflect heavy investment in R&D (estimated 15-18% of revenue), direct sales force expansion (60+ reps in US), and integration costs from recent acquisitions.
Quarterly revenue growth rates and guidance - market expects sustained 20-30%+ growth to justify valuation; any deceleration triggers selloffs
New product launches and FDA clearances - particularly in higher-margin spine segment or international expansion products
Acquisition announcements - KIDS has been serial acquirer of pediatric portfolios (Orthex, Vilex, Telos); integration success and revenue synergies drive sentiment
Surgeon adoption metrics and sales force productivity - new surgeon adds and revenue per rep indicate market penetration progress
Path to profitability updates - with negative FCF of -9.6%, investors focus on timeline to positive operating cash flow and EBITDA breakeven
Reimbursement pressure from government and commercial payers - CMS and private insurers increasingly scrutinize orthopedic implant pricing; bundled payment models could compress hospital willingness to pay premium prices for pediatric-specific devices versus adapted adult products
Limited addressable market size - pediatric orthopedics represents <5% of total orthopedic market; only ~3,000 specialized surgeons globally limits ultimate revenue ceiling compared to adult-focused competitors with 10x larger TAMs
Regulatory pathway complexity - pediatric device approvals face additional scrutiny and longer timelines; any FDA enforcement changes or safety concerns in orthopedic implants could delay product launches
Large orthopedic companies entering pediatric segment - Medtronic, Stryker, or DePuy Synthes could leverage scale and existing hospital relationships to launch competing pediatric lines, though historically they've avoided this low-volume niche
Surgeon concentration risk - with only 3,000 pediatric orthopedic surgeons globally, loss of key opinion leaders or failure to convert new surgeons to KIDS products significantly impacts growth trajectory
International distributor execution - ~25% of revenue flows through third-party distributors in ex-US markets; distributor underperformance or relationship losses create revenue volatility
Cash burn sustainability - negative operating cash flow and -9.6% FCF yield require eventual equity raises or debt financing if path to profitability extends beyond current projections; dilution risk for existing shareholders
Acquisition integration execution - serial M&A strategy creates integration risks including product line rationalization, sales force disruption, and potential goodwill impairments if acquired portfolios underperform
low-to-moderate - Pediatric orthopedic procedures are largely non-discretionary (trauma from accidents, progressive scoliosis requiring intervention), providing recession resilience. However, elective procedures like limb lengthening or early-stage deformity corrections may see modest deferrals during economic stress when families face insurance coverage gaps or high-deductible plans. Hospital capital equipment budgets can tighten in recessions, potentially slowing instrument set placements. Overall, the medically necessary nature of most pediatric orthopedic surgeries insulates revenue from GDP fluctuations more than adult elective orthopedics.
Rising rates create moderate headwinds through two channels: (1) Higher cost of capital pressures valuation multiples for unprofitable growth companies - KIDS trades on forward revenue multiples given negative earnings, making it sensitive to discount rate changes. (2) Modest impact on hospital capital budgets as borrowing costs increase for facility expansions or equipment purchases. However, the company's strong current ratio of 7.40 and low debt/equity of 0.28 minimize direct financing cost impacts. The primary sensitivity is valuation compression as investors rotate from growth to profitable value stocks when rates rise.
Minimal direct credit exposure - KIDS sells to hospitals and ASCs with established payment systems, not consumers. Hospital credit quality affects payment cycles but rarely results in bad debt given healthcare system stability. The company's own balance sheet shows low leverage (0.28 D/E) and strong liquidity (7.40 current ratio), reducing refinancing risk. Broader credit market conditions matter primarily for acquisition financing - tighter credit could limit M&A capacity, which has been a key growth driver.
growth - Investors are paying 1.9x price/sales for a company with 37.6% revenue growth but negative profitability, indicating growth-at-reasonable-price (GARP) positioning. The stock attracts healthcare specialists focused on niche medical device plays with defensible market positions and long-term operating leverage stories. Not suitable for value investors given negative earnings, nor income investors given no dividend. The -30.7% one-year return suggests momentum investors have exited, leaving fundamental long-term holders focused on the 2027-2028 profitability inflection story.
high - Small-cap medical device companies with negative profitability exhibit elevated volatility driven by quarterly revenue beats/misses, binary FDA approval events, and acquisition announcements. The stock's -30.7% one-year return versus +5.2% three-month return demonstrates significant swings. Limited analyst coverage and low institutional ownership in micro-cap healthcare create liquidity-driven volatility. Beta likely exceeds 1.3-1.5x relative to broader market given growth stock characteristics and small-cap risk premium.
